Praxis Precision Medicines (PRAX) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical and regulatory milestones in 2025, including positive readouts for ulixacaltamide, relutrigine, and vormatrigine, and accelerated development for elsunersen.

• Submitted two NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs) following positive Phase 3 and registrational data.

• Pre-launch and commercial preparations for both drugs are underway, with robust activities and infrastructure build-out planned through 2026.

• Vormatrigine and elsunersen clinical programs progressing, with multiple pivotal trial readouts expected in the next 12-18 months, including POWER1 and EMBRAVE data.

• Four late-stage assets have a combined revenue potential exceeding $20 billion.

Financial highlights

• Q4 2025 operating expenses were $97M ($77.5M R&D, $19.5M G&A), up from $71.4M in Q4 2024.

• Full-year 2025 operating expenses totaled $326M, compared to $209M in 2024, driven by increased R&D investment.

• Cash and investments totaled $926M at year-end 2025, up from $469M a year earlier, boosted by public offerings.

• January 2026 public offering added $621M, bringing pro forma cash to ~$1.5B, funding operations into 2028.

• Net loss for 2025 was $303.3M, compared to $182.8M in 2024.

Outlook and guidance

• Expect significant increase in spend in 2026 for commercial launch activities and pipeline progression.

• Commercial launches for ulixacaltamide and relutrigine anticipated pending FDA approval.

• Topline results for vormatrigine and elsunersen expected in the first half of 2026, with potential NDA submissions in the next two years.

• POWER2 enrollment to complete by year-end; EMERALD trial for relutrigine to support sNDA by 2027.

• Planning R&D and commercial days next quarter to discuss pipeline and launch strategies.